Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Enlivex Ltd. (ENLV): What to Expect from Q3 2026 Earnings

Enlivex Ltd. (ENLV): What to Expect from Q3 2026 Earnings

Key Takeaways

  • Enlivex Ltd. (ENLV) is expected to report its third-quarter 2026 results in early December, with consensus calling for a loss of roughly $0.28 per share.
  • As a clinical-stage company with no approved product, Enlivex generates little to no revenue, so investors will focus on operating expenses and cash burn rather than top-line sales.
  • The spotlight remains on Allocetra™, the company's macrophage reprogramming cell therapy, now centered on a Phase 2b trial in age-related knee osteoarthritis.
  • A 1-for-16 reverse stock split (effective October 27, 2026) and a cost reduction plan have meaningfully reshaped the company's share count and spending profile.
  • Enlivex's "dual-engine" strategy, pairing its clinical pipeline with a prediction-markets treasury tied to the RAIN token, can drive large swings in reported net income that are unrelated to operations.
  • Any updates on trial timelines, cash runway, or financing will likely be the biggest drivers of the post-earnings reaction.
  • For deeper context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
  • You can also discover AI-driven trading strategies by exploring Trending AI Robots.

Why This Earnings Report Matters

Enlivex Ltd. (ENLV), an Israel-based clinical-stage biopharmaceutical company, sits at an unusual intersection of drug development and digital-asset treasury management. Its core program, Allocetra™, aims to reprogram macrophages back to a balanced, healthy state, with its lead indication now focused on age-related knee osteoarthritis. Because the company is pre-revenue, its quarterly results are less about sales and more about cash burn, clinical execution, and the value of its treasury holdings. For investors, this report offers a checkpoint on whether management's cost reductions are translating into a longer cash runway and whether the Allocetra development plan remains on schedule heading into anticipated 2027 data readouts.

Earnings Expectations and What to Watch

Analysts expect Enlivex to post a loss of approximately $0.28 per share for the third quarter of 2026, with essentially no meaningful product revenue, reflecting the company's pre-commercial stage. Given the 1-for-16 reverse stock split completed in late October 2026, investors should be cautious when comparing per-share figures to prior periods, as historical results have not necessarily been restated on a comparable basis in every third-party data feed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Rather than revenue, the key metrics to watch are operating expenses, research and development spending, general and administrative costs, and net cash burn. Enlivex announced a cost reduction plan aimed at reducing its workforce by roughly 60% to focus resources on the Phase 2b osteoarthritis trial, so the upcoming report will be a first meaningful test of whether those savings are materializing. The company's bottom line can also be heavily influenced by fair-value changes in its RAIN token treasury, which previously produced a dramatic one-time profit that had little connection to its drug pipeline.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious. ENLV shares have endured extreme volatility over the past year, compounded by the reverse split, a shrinking cash position, and dilution concerns from recent registration filings. The company's dual exposure to biotech clinical risk and the volatile RAIN token treasury adds an extra layer of unpredictability that many traditional healthcare investors find difficult to model. Heading into earnings, the market will be watching for signals that the cost reduction plan is working and that the company has a credible path to fund the osteoarthritis trial without excessive further dilution. Any negative surprise on cash runway or trial timing could weigh on the stock, while a clear, well-capitalized roadmap could ease investor anxiety.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, several factors will shape Enlivex's trajectory. First is the clinical timeline: the company has indicated top-line data from the Phase 2b osteoarthritis trial is expected in 2027, and any confirmation or adjustment of that schedule will matter greatly to investors.

Second is the balance sheet. With no product revenue, Enlivex depends on its cash position and financing options to sustain operations. The effectiveness of the cost reduction plan and the pace of net cash burn will determine how far existing resources extend before additional capital is needed.

Third is the digital-asset treasury. Because the value of the company's RAIN token holdings can swing sharply, reported net income may remain disconnected from the underlying operating business, adding volatility that investors must weigh separately from clinical progress.

Finally, regulatory milestones such as the previously granted Regenerative Medicine Advanced Therapy (RMAT) designation remain relevant. Monitoring trial enrollment, safety updates, and any partnership or financing announcements will help investors assess whether the dual-engine strategy is strengthening the company's runway or concentrating its risk.

My Take on AI Tools for Biotech Analysis

In my ongoing research on names like ENLV, I frequently turn to Tickeron’s AI Screener to quickly filter for technical patterns, fundamentals, and volatility signals across the sector. It helps surface comparable setups ahead of events like earnings or trial updates without requiring hours of manual screening. This kind of tool has become a regular part of how I cross-check ideas and identify what else might be moving in tandem.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ENLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ENLV in upward trend: price may jump up because it broke its lower Bollinger Band on October 30, 2026

ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ENLV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 69 cases where ENLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ENLV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 86328500
Employees
34
Web
https://www.enlivex.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.